48 results
6-K
EX-99.2
NCNA
NuCana plc
13 May 24
Current report (foreign)
4:13pm
No. 03308778
U.K.
Contents
Strategic report
Directors’ report
Directors’ remuneration report
Statement of directors’ responsibilities
Independent … biliary tract cancer. This decision was made following a pre-planned futility analysis by the study’s Independent Data Monitoring Committee. Although
6-K
EX-99.2
NCNA
NuCana plc
15 May 23
Current report (foreign)
4:11pm
.
Contents
Strategic report
Directors’ report
Directors’ remuneration report
Statement of directors’ responsibilities
Independent auditor’s report … locally advanced or metastatic biliary tract cancer. This decision was made following a pre-planned futility analysis by the study’s Independent Data
6-K
EX-99.2
5ugy1okjun57
2 Jun 22
Unaudited Condensed Consolidated Statements of Operations
4:05pm
6-K
EX-99.1
4n20pnasu
2 Mar 22
NuCana Announces Update for Phase 3 Biliary Tract Cancer Study
4:05pm
F-3
EX-4.7
7xup2zhv8
19 Aug 21
Shelf registration (foreign)
4:50pm
F-3
EX-23.1
mre9 gvf59s7e46
19 Aug 21
Shelf registration (foreign)
4:50pm
F-3
EX-4.6
2g7qzev vuky6
19 Aug 21
Shelf registration (foreign)
4:50pm
F-3
EX-1.2
jm56o93 v9kt9c
19 Aug 21
Shelf registration (foreign)
4:50pm
F-3
utyld
19 Aug 21
Shelf registration (foreign)
4:50pm
6-K
EX-99.3
bnq wq3sc
19 Aug 21
Unaudited Condensed Consolidated Statements of Operations
4:28pm
6-K
EX-1.1
ahczo efiwyomz
18 Sep 20
NuCana Announces Pricing of a Public Offering of American Depositary Shares
4:15pm
424B5
sfxamzf g1jgn1
17 Sep 20
Prospectus supplement for primary offering
4:50pm